SAN FRANCISCO–(BUSINESS WIRE)– #aging–Revel Pharmaceuticals today announced a study published by its scientists as well as researchers at Calico and the University of Colorado Anschutz Medical Campus, in Nature Communications. The paper describes CMLase, an engineered enzyme that reverses a stable form of chemical damage that builds up in long-lived proteins over decades. The damage, known as Nε-carboxymethyl-lysine (CML), is a type of advanced glycation end product (“AGE”). It forms when sugars reac
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
